Like the well-understood PD-1/PD-L1 pathway in cancer immunotherapy, the novel CD112R-CD112 pathway, which is still being studied (Table 2), might gain popularity regarding tumor immunotherapy shortly. This evidence concerns the gene PVRIG and neoplasm.